MarketFriction

J B Chemicals & Pharmaceuticals Ltd

NSE JBCHEPHARM · BSE 506943 · Pharmaceuticals
₹2,408.90 -3.87%
NSE close2026-07-16
Market cap₹38,677 Cr.
P/E53.8
No trades in 30 days Delivery 66.8%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales8968828458621,0041,0019639491,0941,0851,065904
Expenses664638621664724730709723793775769703
Operating Profit232244223198280271255226301310296201
OPM %26%28%26%23%28%27%26%24%28%29%28%22%
Other Income68717610814151518-15
Interest121012962311121
Depreciation313234414142424643444550
Profit before tax194209184165240237218193272279267135
Tax %27%28%27%23%26%26%25%25%25%26%26%25%
Net Profit142151134126177175162146202208198101
EPS in Rs9.199.728.628.1311.3911.2410.459.3612.9613.2712.636.31
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales1,1441,2101,3441,4081,6431,7752,0432,4243,1493,4843,9184,148
Expenses9641,0041,1121,1911,3371,3971,4821,8812,4542,5872,8863,040
Operating Profit1802062322183063785605436968971,0321,107
OPM %16%17%17%15%19%21%27%22%22%26%26%27%
Other Income1158503741411123910373833
Interest7115353753644126
Depreciation3941475756666973114138171182
Profit before tax146212230194287349597505555752887952
Tax %31%23%20%28%32%22%25%24%26%26%26%26%
Net Profit100163184139194272449386410553660709
EPS in Rs5.929.5810.858.2712.0617.6028.9824.9326.4835.6142.3644.18
Dividend Payout %118%26%5%12%21%31%28%33%34%34%37%50%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth13%15%10%6%
Compounded Profit Growth18%12%21%15%
Stock Price CAGR30%21%18%41%
Return on Equity18%19%19%19%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital171717171615151515161616
Reserves9781,1671,3471,4251,4641,4201,7942,1192,4652,9083,4184,143
Borrowings127193492926294555572378284
Other Liabilities365270262294286349376412495687804799
Total Liabilities1,4871,6481,6741,7651,7921,8142,2312,6013,5473,9884,2654,962
Fixed Assets3294406796406216516341,2771,9012,0041,9681,885
CWIP551354171516261955766374
Investments55247941143445740367813206388345765
Other Assets5525945806746997438941,2931,3851,5191,8892,237
Total Assets1,4871,6481,6741,7651,7921,8142,2312,6013,5473,9884,2654,962
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity127140201123194276315170626801902704
Cash from Investing Activity-112-26-45-21-2824-2312-962-404-296-586
Cash from Financing Activity-1-100-184-60-156-306-87-138357-385-580-123
Net Cash Flow1315-284311-6-334201127-5
Free Cash Flow56-634894153205315-529-138540783623
CFO/OP91%94%107%75%85%97%81%56%104%104%107%87%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days848272786871708467727669
Inventory Days122146138145149159181178134155147192
Days Payable637168757297979775110114110
Cash Conversion Cycle143158142148146133153164127117109151
Working Capital Days16387593918191122815579126
ROCE %13%15%14%11%18%23%33%23%22%25%26%25%
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters53.91%53.86%53.83%53.78%53.77%53.74%53.66%47.84%47.73%47.56%47.55%48.80%
FIIs9.53%10.05%10.35%11.06%12.17%13.63%14.64%18.30%17.77%15.31%14.88%16.33%
DIIs18.65%18.58%18.53%18.38%17.61%16.81%16.40%18.71%19.62%22.83%23.35%21.38%
Government0.00%0.00%0.00%0.01%0.00%0.01%0.00%0.00%0.00%0.00%0.00%0.00%
Public17.90%17.50%17.27%16.78%16.42%15.80%15.29%15.13%14.87%14.31%14.21%13.48%
No. of Shareholders55,96560,81763,23063,89266,95362,74362,08163,94870,06471,95769,33874,043

Fundamentals

Market Cap₹ 38,677 Cr.
Current Price₹ 2,409
Stock P/E53.8
Book Value₹ 259
ROCE25.4 %
ROE18.9 %
Dividend Yield0.91 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)6%
Compounded Profit Growth (TTM)15%
Consolidated figures.
Valuation
Market capRs 38,677 Cr
Enterprise valueRs 38,535 Cr
P/E (TTM)54.52x
Price to book9.30x
Price to sales9.32x
EV / EBITDA33.79x
EV / EBIT40.23x
EV / sales9.29x
Price to cash flow54.95x
Earnings yield1.83%
Dividend yield0.91%
P/E, 3-year average43.79x
P/B, 3-year average8.03x
P/E, 5-year average33.17x
P/B, 5-year average6.01x
Profitability
Operating margin (excl. other income)26.70%
Operating margin (incl. other income)27.49%
EBITDA margin27.49%
Pre-tax margin22.96%
Net profit margin17.10%
Net margin, latest quarter11.21%
ROE18.69%
ROCE25.13%
ROA15.38%
ROE, 3-year average19.96%
ROCE, 3-year average25.59%
ROA, 3-year average15.34%
ROE, 5-year average19.44%
ROCE, 5-year average24.91%
ROA, 5-year average15.06%
ROIC (approx.)17.77%
Tax rate25.50%
Other income / net worth0.79%
Growth
Sales growth (latest year)5.87%
Profit growth (latest year)7.56%
Sales CAGR, 3 years9.61%
Sales CAGR, 5 years15.22%
Profit CAGR, 3 years20.07%
Profit CAGR, 5 years9.63%
Sales growth QoQ-15.07%
Profit growth QoQ-48.77%
Sales growth YoY (latest quarter)-4.77%
Profit growth YoY (latest quarter)-30.42%
Per share
EPS (TTM)Rs 44.19
EPS (latest year)Rs 44.19
EPS (latest quarter)Rs 6.31
EPS, 3-year averageRs 40.72
EPS, 5-year averageRs 45.00
Book value per shareRs 259.05
Sales per shareRs 258.33
Cash flow per shareRs 43.84
Free cash flow per shareRs 38.80
Dividend per share (latest year)Rs 22.01
Dividend per share, 3-year averageRs 16.59
Dividend per share, 5-year averageRs 16.80
Dividends
Dividend payout49.80%
Dividend payout, 3-year average40.26%
Dividend payout, 5-year average37.48%
Efficiency
Asset turnover0.84x
Fixed asset turnover2.20x
Inventory turnover2.26x
Inventory days162 days
Debtor days69 days
Debtors turnover5.31x
Creditor days110 days
Cash conversion cycle151 days
Working capital days126 days
Leverage
Total debtRs 4 Cr
Cash and bankRs 146 Cr
Net debtRs -142 Cr
Debt to equity0.00x
Net debt / EBITDA-0.12x
Interest coverage171.97x
Owners' fund to total sources83.83%
Debt to assets0.07%
Cash flow
Cash from Operating Activity (latest year)Rs 704 Cr
Cash from Investing Activity (latest year)Rs -586 Cr
Cash from Financing Activity (latest year)Rs -123 Cr
Net Cash Flow (latest year)Rs -5 Cr
Free cash flow (latest year)Rs 623 Cr
FCFE (approx.: FCF + change in debt)Rs 599 Cr
Cash from ops / profit, 5 years1.18x
Sales to cash flow5.89x
Statement figures
Net sales (TTM)Rs 4,148 Cr
Net sales (latest year)Rs 4,148 Cr
Sales (latest quarter)Rs 904 Cr
Operating profit excl. other income (latest year)Rs 1,107 Cr
Operating profit (latest quarter)Rs 201 Cr
Other income (TTM)Rs 33 Cr
EBITDA (TTM)Rs 1,140 Cr
PBDT (TTM)Rs 1,135 Cr
Profit before tax (TTM)Rs 952 Cr
Tax (latest year)Rs 243 Cr
Net profit (TTM)Rs 709 Cr
Net profit (latest year)Rs 709 Cr
Net profit (latest quarter)Rs 101 Cr
Depreciation (TTM)Rs 182 Cr
Depreciation (latest quarter)Rs 50 Cr
Interest (TTM)Rs 6 Cr
Cost of goods sold (latest year)Rs 1,544 Cr
Total expenditure (latest year)Rs 3,040 Cr
Total income (latest year)Rs 4,181 Cr
Share capitalRs 16 Cr
ReservesRs 4,143 Cr
Shareholders' fundsRs 4,159 Cr
Total assetsRs 4,962 Cr
Net blockRs 1,885 Cr
Capital work in progressRs 74 Cr
InvestmentsRs 765 Cr
ReceivablesRs 781 Cr
InventoryRs 683 Cr
Other liabilitiesRs 799 Cr
Shares outstanding (crore)16.06
Ownership
Promoter holding48.80% (+0.96 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 54.5 is at the 88th percentile of its own 9.2-year range (median 32.5, low 12.0, high 74.6).
P/B 9.30 is at the 81th percentile (median 7.29).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodJBCHEPHARMNifty 50Difference
1 week-1.5%-2.8% +1.3 pts
1 month+9.9%-6.8% +16.6 pts
3 months+21.6%-7.6% +29.2 pts
6 months+24.6%+0.4% +24.2 pts
1 year+47.5%-9.9% +57.5 pts
2 years+38.2%-13.6% +51.8 pts
3 years+87.1%+14.2% +73.0 pts
5 years+154.6%+27.9% +126.7 pts

Red flags

F-score 4 of 8
No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Mar 2026
Sales ₹904 Cr -4.7% vs Mar 2025. Net profit ₹101 Cr -30.8%.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-05-29Dividend - Rs 9.30 Per Share
2026-02-11Interim Dividend - Rs 12.70 Per Share
2025-07-30Dividend - Rs 7 Per Share
2025-02-07Interim Dividend - Rs 8.50 Per Share
2024-08-14Dividend - Rs 6.75 Per Share
2024-02-16Interim Dividend - Rs 5.50 Per Share
2023-09-18Face Value Split (Sub-Division) - From Rs 2/- Per Share To Re 1/- Per Share0.5000
2023-08-17Dividend - Rs 9.25 Per Share
2023-02-17Interim Dividend - Rs 8.50 Per Share
2022-08-12Dividend - Rs 8 Per Sh
2022-02-23Interim Dividend - Rs 8.50 Per Share
2021-09-01 Annual General Meeting/Dividend - Rs 8 Per Share
2021-02-18 Interim Dividend - Rs. 8.50 Per Share
2020-09-22 Annual General Meeting/Dividend - Re 1 Per Share
2020-03-03 Interim Dividend - Rs 10 Per Share
2019-11-21 Buyback
2019-08-14 Dividend - Rs 5 Per Share
2018-09-11 Buyback
2018-08-27 Dividend Rs 2/- Per Share
2017-09-11 Annual General Meeting/Dividend - Re 1/- Per Share
2017-06-01 Buyback
2016-08-11 Dividend - Re 0.50/- Per Share
2016-03-17 Interim Dividend -Rs 4.50/- Per Share (Purpose Revised)
2015-08-06Annual General Meeting/Final Dividend Rs.4/- Per Share And Special Dividend Rs.10/- Per Share
2014-09-04Annual General Meeting / Dividend - Rs 3/- Per Share
2013-08-01Annual General Meeting / Dividend - Rs 3/- Per Share
2012-07-19Annual General Meeting/Dividend Re 1 Per Share
2011-08-29Special Interim Dividend Rs.40/- Per Share
2011-07-14Annual General Meeting And Dividend Rs.2/- Per Share
2010-07-15Annual General Meeting And Dividend Rs.2/- Per Share
2009-07-02Agm/Div-Re.1/- Per Share
2008-07-03Dividend - 25%
2007-07-12Fin Div-Rs.1.50 Per Sh
2006-11-13Int Div-Rs.1.10 Per Sh
2006-06-29Fin Div-Rs.1.50/- Per Sh
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of J B Chemicals & Pharmaceuticals Ltd?

J B Chemicals & Pharmaceuticals Ltd (JBCHEPHARM) has a market capitalisation of Rs 38,677 Cr. at the 2026-07-16 close.

What is the P/E ratio of J B Chemicals & Pharmaceuticals Ltd?

J B Chemicals & Pharmaceuticals Ltd trades at a P/E of 53.8 on trailing twelve-month profit, at the 2026-07-16 close.

What were J B Chemicals & Pharmaceuticals Ltd's latest quarterly results?

In the Mar 2026 quarter, J B Chemicals & Pharmaceuticals Ltd sales was Rs 904 Cr (-4.7% vs Mar 2025) and net profit was Rs 101 Cr.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03